Tonix publishes investor deck highlighting TONMYA fibromyalgia launch and pipeline updates
TNXP•Cash position and pipeline updates
- Cash and cash equivalents of about $185.5 million as of March 31, 2026; no debt; runway expected into early Q2 2027.
- Pipeline updates include TNX-4800 Lyme prevention Phase 2 planned Q1 2027; TNX-1500 transplant rejection Phase 2 planned 2H 2026.
TONMYA launch and early prescription data
Tonix highlighted TONMYA, a sublingual cyclobenzaprine product launched Nov. 17, 2025 for fibromyalgia in adults.
- TONMYA net sales of $3.7 million in Q1 2026; $5.1 million from Nov. 17, 2025 to March 31, 2026.
- Since launch, more than 2,600 prescribers; about 11,016 prescriptions through May 1, 2026; about 5,618 patients through April 24, 2026.
